LENZ Therapeutics, Inc. (LENZ) - Dilution Analysis

10-Q filing | 31.4M shares outstanding

10-K filing | 28.8M shares outstanding

10-Q filing | 28.5M shares outstanding

8-K filing: On October 7, 2025, the Company sold 1,748,634 shares of common stock at a purchase price of $45.75 per share for gross proceeds of approximately $80,000,000 in a block trade to a single investor under the Company's "at the market" Sales Agreement with TD Securities (USA) LLC. ($80.0M proceeds)

10-Q filing | 27.5M shares outstanding

S-3 filing: This S-3 filing pertains to an offering of 13,070,093 shares of Common Stock, consisting of (i) 12,922,451 shares of Common Stock held by the selling securityholders and (ii) 147,642 shares of Common Stock issuable upon the exercise of outstanding warrants held by the selling securityholders. The company will not receive any proceeds from the sale of these shares.

POS AM filing: This POS AM filing relates to the offering of 1,578,947 shares of common stock issued in the July 2024 PIPE Financing, which were initially registered in the Initial Registration Statement. No new shares are being registered hereunder, and the company will not receive any proceeds from the sale of these shares.

POS AM filing: This POS AM filing registers 1,022,809 shares of common stock issued in a PIPE financing, with no proceeds going to the company. The filing also notes that as of December 31, 2024, there were 27,531,490 shares of common stock outstanding.

S-3 filing: S-3 filing for an at-the-market offering of common stock with an aggregate offering price of up to $150,000,000.

10-K filing | 27.5M shares outstanding

10-Q filing | 27.2M shares outstanding

S-1 filing: This prospectus relates to the resale by the selling stockholder of 1,578,947 shares of common stock that were sold and issued to the selling stockholder in a private placement pursuant to a stock purchase agreement, dated July 14, 2024, which closed on July 17, 2024. We will not receive any of the proceeds from the sale of the securities by the selling stockholder.

10-Q filing | 25.6M shares outstanding

8-K filing: LENZ Therapeutics, Inc. entered into a Stock Purchase Agreement for a private placement with Ridgeback Capital Investment, L.P. to sell 1,578,947 shares of common stock at $19.00 per share, with gross proceeds of approximately $30.0 million, expected to close on July 17, 2024. ($30.0M proceeds)

10-Q filing | 25.5M shares outstanding

S-1/A filing: This prospectus relates to the resale by certain selling securityholders of 1,297,411 shares of common stock issued in the PIPE Financing. The company will not receive any proceeds from the sale of these shares.

S-1 filing: This S-1 filing registers the resale of 1,297,411 shares of common stock by selling securityholders.

8-K filing: Stock split 1:7 | Outstanding: 57,015,159 → 25,533,533

10-K filing | 57.0M shares outstanding

10-Q filing | 57.3M shares outstanding

10-Q filing | 56.7M shares outstanding

10-Q filing | 55.9M shares outstanding

10-K filing | 54.9M shares outstanding

10-Q filing | 55.2M shares outstanding

10-Q filing | 54.6M shares outstanding

S-3 filing: The filing is for a shelf offering of common stock, preferred stock, and debt securities with an aggregate principal amount of up to $300,000,000.

10-Q filing | 58.0M shares outstanding

10-K filing | 58.0M shares outstanding

10-Q filing | 58.1M shares outstanding

10-Q filing | 58.1M shares outstanding

S-1/A filing: This is an S-1/A filing for an IPO of common stock with 12,500,000 shares offered, and an underwriter over-allotment option of 1,875,000 shares. The company estimates net proceeds of $182.7 million, or $210.6 million if the over-allotment is exercised, assuming an IPO price of $16.00 per share.

S-1/A filing: This S-1/A filing outlines an offering of common stock, with 12,500,000 shares offered initially and an additional 1,875,000 shares available through an underwriter's over-allotment option, and intends to use the net proceeds from this offering, including our existing cash and cash equivalents, to fund our clinical development of GPH101 for the treatment of SCD, GPH201 for the treatment of XSCID and GPH301 for the treatment of Gaucher disease, to fund our current discovery programs in CCR5 and alpha globin, and for working capital and general corporate purposes.

S-1/A filing: This S-1/A filing relates to an offering of common stock, with the number of shares and price per share to be determined. The company intends to use the net proceeds from this offering to fund clinical development, discovery programs, and for working capital and general corporate purposes.

S-1 filing: This S-1 filing includes information about a proposed offering of common stock, the use of proceeds from the offering, risk factors, and summary financial data.